Home News & Features

News & Features

Antibodies responding to covid-19 coronavirus, illustration

Promising New Rapid COVID-19 Serological Test Data Released

Scientists in Singapore and China validated the test across two patient cohorts, with a sample size of 250 from China and 375 from Singapore, and found it achieved 99.93% specificity and 95–100% sensitivity and differentiated antibody responses to several human coronaviruses.

T Cells That Recognize SARS-CoV-2 May Be Leftover from Past Coronavirus Infections

The researchers found that one in three people with no prior exposure to SARS-CoV-2 nonetheless has T-helper cells capable of recognizing the virus. The likely reason for this is that SARS-CoV-2 shares certain structural similarities with other coronaviruses.
A new study utilized electronic medical records and genotype data to reveal three patient subtypes of type 2 diabetes. [iStock/dml5050]

Researchers Track Metabolic Link Between Type 2 Diabetes and Fatty Liver Disease

A new study from the Faculty of Health and Medical Sciences at the University of Copenhagen shows that glucagon resistance may be the link between type 2 diabetes and non-alcoholic fatty liver disease.
Antibodies responding to coronavirus particles, illustration

Humanigen Attempts Revival via Battle Against COVID-19

The company is currently testing whether its engineered antibody or “Humaneered” technology developed over two decades can catapult the company to a leading role in the scramble to conquer COVID-19.
Doctor preparing a vaccine for an injection

AstraZeneca’s COVID-19 Vaccine Candidate Enters 30,000-Person Phase III Trial

The trial will be conducted at 62 study centers in up to 30,000 adults aged 18 years and older from diverse racial, ethnic, and geographic groups who are healthy, or have stable underlying medical conditions, and including those at increased risk of infection from SARS-CoV-2.
coronavirus,3d render

Large Phase III Trial Launched for J&J’s COVID-19 Vaccine

J&J’s Janssen has moved into Phase III with its single-dose COVID-19 vaccine candidate, which it plans to test in up to 60,000 study participants in eight countries, to evaluate its safety and efficacy compared with placebo.
Electron microscopy virus visualization

Gene Expression Studies Reveal New COVID-19 Inflammatory Response Pathway

The team, led by Dan Jacobson of the Department of Energy's Oak Ridge National Laboratory, found that genes in the bradykinin system were excessively activated in the lung fluid cells of COVID-19 patients.

“Warp Speed” Plows $2.1B into Supporting Sanofi, GSK COVID-19 Vaccine Trial

The Sanofi-GSK vaccine combines Sanofi’s S-protein COVID-19 antigen, which is based on recombinant DNA technology, and GSK’s pandemic AS03 adjuvant.
Coronavirus Covid-19 Vaccine

AstraZeneca, U. of Oxford; Pfizer, BioNTech Ramp up COVID-19 Vaccine Trials

AstraZeneca and the University of Oxford resumed the clinical study they paused last week after one U.K. participant developed a “potentially unexplained illness,” while Pfizer and BioNTech have requested FDA approval to add 14,000 participants to their late-stage study.
remdesivir covid-19 liquid medication background

NIH Launches Remdesivir Plus Interferon Beta-1a Trial for COVID-19 Treatment

The study, called the Adaptive COVID-19 Treatment Trial 3 (ACTT 3), is anticipated to enroll more than 1,000 hospitalized adults with COVID-19 at as many as 100 sites in the United States and abroad.
Scroll Up